Characterization of the activity of KTX-1001, a small molecule inhibitor of multiple myeloma SET domain using surface plasmon resonance
Open Access
- 14 June 2025
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (7) , 110382
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)Journal of Medicinal Chemistry, 2023
- Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2Journal of the American Chemical Society, 2023
- Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2Nature Communications, 2021
- NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesisMolecular Cell, 2021
- Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2Journal of Medicinal Chemistry, 2021
- NSD2 is a conserved driver of metastatic prostate cancer progressionNature Communications, 2018
- Structure of the Epigenetic Oncogene MMSET and Inhibition by N-Alkyl Sinefungin DerivativesACS Chemical Biology, 2016
- Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemiaNature Genetics, 2013
- MMSET is the key molecular target in t(4;14) myelomaBlood Cancer Journal, 2013
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic ProgrammingMolecular Cell, 2011